Ikarian Capital’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History

Ikarian Capital’s Portfolio TCON Stock Details TCON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-138,277	Closed	-$484K	–	185
2023 Q4	$484K	Hold	138,277	–	–	0.05%	116
2023 Q3	$492K	Hold	138,277	–	–	0.06%	114
2023 Q2	$805K	Hold	138,277	–	–	0.13%	88
2023 Q1	$5.23M	Hold	138,277	–	–	1.19%	27
2022 Q4	$4.12M	Hold	138,277	–	–	0.99%	32
2022 Q3	$4.62M	Sell	138,277 -1,166	-0.8%	-$44.5K	0.92%	38
2022 Q2	$5.58M	Sell	139,443 -2,719	-2%	-$105K	1.02%	32
2022 Q1	$7.48M	Buy	142,162 +7,606	+6%	+$382K	0.98%	28
2021 Q4	$7.45M	Hold	134,556	–	–	1.11%	24
2021 Q3	$10.4M	Sell	134,556 -1,286	-0.9%	-$109K	0.73%	36
2021 Q2	$17.6M	Hold	135,842	–	–	1.43%	15
2021 Q1	$22.4M	Hold	135,842	–	–	0.75%	32
2020 Q4	$31.8M	Buy	135,842 +27,715	+26%	+$3.86M	1.4%	12
2020 Q3	$11.2M	Buy	+108,127	New	+$5.79M	0.81%	35

Other funds holding TCON

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Ikarian Capital's TCON Position: Q1 2024 in Review

Ikarian Capital sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q1 2024, closing a stake of 138,277 shares — an estimated $484K sold.

Ikarian Capital first reported a position in TCON in Q3 2020 and held it in 14 quarters. The position peaked at $31.8M in Q4 2020. 29 funds tracked by Wall St. Rank hold TCON as of Q1 2024.

Ikarian Capital reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Ikarian Capital sold 138,277 TRACON Pharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $484K.
Ikarian Capital first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q3 2020 and held it in 14 quarters.
Ikarian Capital's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $31.8M in Q4 2020.
29 funds tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on Ikarian Capital's 13F filing for Q1 2024, filed 15 May 2024.